

# Iminophosphorane-Mediated Synthesis of 1-Substituted- $\beta$ -Carbolines: Investigative Studies on the Preparation of Alkaloids Lavendamycin and Eudistomins Framework.

Pedro Molina\*, Pilar M. Fresneda, Mercedes Cánovas

Departamento de Química Orgánica, Facultad de Química, Universidad de Murcia,


Campus de Espinardo, E-30071, Murcia, Spain.

**Abstract.**- Aza-Wittig reaction of iminophosphorane **3**, derived from ethyl  $\alpha$ -azido- $\beta$ -(3-indolyl) propenoate and tri-phenylphosphine, with 2-formylpyrrole and 2-formylquinolines leads to Eudistomins A and M and Lavendamycin derivatives respectively.

Alkaloids containing a  $\beta$ -carboline ring system substituted at position 1 by a heteroaryl ring represent an important class of compounds which display interesting biological activities. Lavendamycin **1**, isolated from *Streptomyces Lavendulae* and structurally and biogenetically related to Streptonigrin, displays an important antimicrobial and antitumor activity against P-388 and L-1210<sup>1</sup>, consequently it has been the focus of synthetic


efforts since its initial structural identification. Synthetic approaches towards **1** involve either Bischler-Napieralski reaction between  $\beta$ -methyltryptophan and quinaldic acid derivatives<sup>2</sup> or Pictet-Spengler cyclization reaction between  $\beta$ -methyltryptophan and 8-benzyloxy-2-formylquinoline<sup>3</sup> to construct the ring C. A recent total synthesis of **1** involves formation of the B ring by Friedlander cyclization between an o-aminobenzaldehyde possessing suitable functionality and an 1-acetyl- $\beta$ -carboline derivative, available by regioselective inverse electron demand [4+2] cycloaddition followed by palladium (0)-mediated  $\beta$ -carboline synthesis<sup>4</sup>. The alkaloids Eudistomins A and M **2** which contain the rare 1-pyrrolinyl- $\beta$ -carboline ring system, have been isolated<sup>5</sup> from the active antiviral Caribbean tunicate *Eudistoma Olivaceum*. The Eudistomin M has been prepared<sup>6</sup> in five-steps from 6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline-1-carboxylic acid.

In the course of our studies directed towards the synthesis of fused heterocycles based on heterocyclization reaction of unsaturated heterocumulenes, we have developed the so-called tandem aza-Wittig/ electrocyclization strategy for the synthesis of pyridines and



isoquinoline derivatives<sup>7</sup>. We now report a slight modification of this strategy, undertaken in order to prepare some 1-substituted  $\beta$ -carboline derivatives of valuable biological interest. Our approach is centered on the Wittig reaction of the iminophosphorane **3** derived from ethyl  $\alpha$ -azido- $\beta$ -(3-indolyl)propenoate with aldehydes to give 2-azahexatrienes which undergo cyclization to give 1-substituted- $\beta$ -carbolines.


The starting iminophosphorane **3**, easily prepared from 3-formyl-1-methyl indole by sequential treatment with ethyl azidoacetate and triphenylphosphine<sup>8</sup>, reacts with aldehydes in toluene at 160°C in a sealed tube to give 1-substituted- $\beta$ -carbolines **4** in 70-88% yields. The conversion **3**→**4** involves initial aza-Wittig reaction to give a 2-azahexatriene which subsequently undergoes electrocyclic ring-closure<sup>9</sup>. Further dehydrogenation under the reaction conditions leads to the  $\beta$ -carbolines **4** (Scheme 1).



Scheme 1

In this way, iminophosphorane **3** also reacts with 2-formylpyrrole to give **5** in 70% yield<sup>10</sup> thus completing the assemblage of the carbon skeleton of Eudistomins A and M.


Reaction between iminophosphorane **3** and 2-formylquinoline derivatives is carried out under the same conditions. It is gratifying to note that the reaction goes smoothly to offer **6a** and **6b**, which contain the Lavendamycin ABCDE framework (Scheme 2).



Scheme 2

The presence in **6b** of a benzyloxy group at C-8 is exploited to introduce bromine at positions C-5 and C-7 which eventually<sup>3</sup> rendered the aminoquinone ring A.

Finally, iminophosphorane **3** reacts with pyruvaldehyde to give the key intermediate 1-acetyl- $\beta$ -carboline **7** in 55% yield<sup>11</sup>, which undergoes aza-Wittig reaction followed by aldol condensation with concomitant hydrolysis of the ester group by the action of the iminophosphorane derived from *o*-azidobenzaldehyde<sup>12</sup> in the presence of sodium ethoxide to give **6c** in 75% yield. Friedlander condensation between **7** and 2-amino-3-benzyloxy-4-bromo benzaldehyde in the presence of benzyltrimethylammonium hydroxide yields **6d** in 61% yields<sup>13</sup> (Scheme 3).



Reagents and conditions: a) pyruvaldehyde, toluene, sealed tube, 160°C; b) *N*-(*o*-formylphenyl)triphenyliminophosphorane, EtOH-NaOEt, -10°C, 30 min  $\rightarrow$  reflux, 18h; c) 2-amino-3-benzyloxy-4-bromobenzaldehyde, THF, benzyltrimethylammonium hydroxide, rt, 18h.

Scheme 3

In conclusion the results reported here show that the tandem aza-Wittig/electrocyclic ring-closure strategy affords a new and versatile entry to a variety of 1-substituted- $\beta$ -carbolines. This method, which is simple and direct, leads from the readily available iminophosphorane **3** to Eudistomin and Lavendamycin derivatives<sup>14</sup>. Further studies are underway in our laboratory which are aimed at the application of this methodology to the formal total synthesis of Eudistomins A and M and Lavendamycin.

#### Acknowledgements:

We gratefully acknowledge the financial support of the Dirección General de Investigación Científica y Técnica (Project Number PB89-0436).

#### References and Notes

- Balitz, D. M.; Bush, J. A.; Bradner, W. T.; O'Herron, F.A.; Nettleton, D. E. *J. Antibiot.* **1982**, *35*, 259; Erickson, W. R.; Gould, S. J. *J. Am. Chem. Soc.* **1985**, *107*, 5831.
- Kende, A. S.; Ebetino, F. H. *Tetrahedron Lett.* **1984**, 923; Rao, A. V. R.; Chavan, S.P.; Sivadasan, L.

*Tetrahedron* **1986**, *42*, 5065.

3. Hibino, S.; Okazaki, M.; Sato, K.; Morita, I.; Ichikawa, M. *Heterocycles* **1983**, *20*, 1957; Hibino, S.; Okazaki, M.; Ichikawa, M.; Sato, K.; Ishizu, T. *Heterocycles* **1985**, *23*, 261.
4. Boger, D.L.; Panek, J. S. *Tetrahedron Lett.* **1984**, 3175; Boger, D. L.; Duff, S. R.; Panek, J. S.; Yasuda, M., *J. Org. Chem.* **1985**, *50*, 5782; Boger, D. L.; Duff, S. R.; Panek, J. S.; Yasuda, M. *J. Org. Chem.* **1985**, *50*, 5790.
5. Kobayashi, J.; Harbour, G. C.; Gilmore, J.; Rinehart Jr, K. L. *J. Am. Chem. Soc.* **1984**, *106*, 1526.
6. Rinehart Jr, K. L.; Kobayashi, J.; Harbour, G. C.; Gilmore, J.; Mascal, M.; Holt, T. G.; Shield, L. S.; Lafargue, F. *J. Am. Chem. Soc.* **1987**, *109*, 3378.
7. Molina, P.; Fresneda, P. M.; Almendros, P. *Tetrahedron* **1991**, *47*, 4175.
8. Molina, P.; Fresneda, P. M. *J. Chem. Soc. Perkin Trans I* **1988**, 1819.
9. Molina, P.; Fresneda, P. M.; Alarcon, P. *Tetrahedron Lett.* **1988**, 379; Barluenga, J.; Ferrero, M.; Palacios, F. *J. Chem. Soc. Perkin Trans I* **1990**, 2193.
10. Compound **5**. <sup>1</sup>H n.m.r. (200 MHz, CDCl<sub>3</sub>) δ 1.38 (t, 3H, <sup>3</sup>J=7.1Hz), 3.82 (s, 3H, CH<sub>3</sub>-N), 4.37 (q, 2H, <sup>3</sup>J=7.1Hz), 6.31 (q, 1H, <sup>3</sup>J=3.2Hz, H-4'), 6.52 (m, 1H, H-3'), 6.94 (m, 1H, H-5'), 7.35 (t, 1H, <sup>3</sup>J=7.4, H-6), 7.47 (d, 1H, <sup>3</sup>J=8.3Hz, H-8), 7.63 (td, 1H, <sup>3</sup>J=7.4Hz, <sup>4</sup>J=0.6Hz, H-7), 8.11 (d, 1H, <sup>3</sup>J=7.8, H-5), 8.48 (s, 1H, H-4), 10.32 (s br, 1H, NH); <sup>13</sup>C n.m.r. (50 MHz, CDCl<sub>3</sub>) δ 14.33 (CH<sub>3</sub>), 33.11 (CH<sub>3</sub>-N), 61.28 (CH<sub>2</sub>), 109.06 (C-4'), 110.40 (C-8), 111.89 (C-3'), 115.17 (C-5'), 119.78 (C-4), 120.79 (C-5), 121.42 (C-6), 121.56 (C-4a), 128.24 (C-2'), 128.78 (C-7), 130.51 (C-4b), 135.70 (C-9a), 136.50 (C-8a), 136.76 (C-3), 143.68 (C-1), 165.86 (CO); m/z (%) 319 (M<sup>+</sup>, 26).
11. Compound **7**. <sup>1</sup>H n.m.r. (200 MHz, CDCl<sub>3</sub>) δ 1.51 (t, 3H, <sup>3</sup>J=7.1Hz), 3.00 (s, 3H, CH<sub>3</sub>-CO), 3.97 (s, 3H, CH<sub>3</sub>N), 4.53 (q, 2H, <sup>3</sup>J=7.1Hz), 7.39 (t, 1H, <sup>3</sup>J=7.4Hz, H-6), 7.54 (d, 1H, <sup>3</sup>J=8.2Hz, H-8), 7.68 (t, 1H, <sup>3</sup>J=7.4Hz, H-7), 8.20 (d, 1H, <sup>3</sup>J=7.7Hz, H-5), 8.96 (s, 1H, H-4); <sup>13</sup>C n.m.r. (50 MHz, CDCl<sub>3</sub>) δ 14.41 (CH<sub>3</sub>), 28.34 (CH<sub>3</sub>-CO), 34.13 (CH<sub>3</sub>-N), 61.61 (CH<sub>2</sub>), 110.44 (C-8), 119.77 (C-4), 120.98 (C-4a), 121.23 (C-6), 121.48 (C-5), 129.47 (C-7), 132.26 (C-4b), 135.87 (C-9a), 136.06 (C-8a), 139.26 (C-3), 143.62 (C-1), 165.45 (COOEt), 201.30 (CO-CH<sub>3</sub>); m/z (%) 269 (M<sup>+</sup>, 61).
12. Luheshi, A. B. N.; Salem, S. M.; Smalley, R. K.; Kennewell, P. D.; Westwood, R. *Tetrahedron Lett.* **1990**, *31*, 6561; Molina P.; Arques A.; Cartagena, I.; Obón, R. *Tetrahedron Lett.* **1991**, 2521.
13. Compound **6d**. <sup>1</sup>H n.m.r. (200 MHz, DMSO-d<sub>6</sub>) δ 3.74 (s, 3H, CH<sub>3</sub>N), 5.17 (s, 2H, PhCH<sub>2</sub>O), 6.90 (d, 2H, <sup>3</sup>J=7.6Hz, 2xH<sub>p</sub>), 7.10 (t, 1H, <sup>3</sup>J=7.3Hz, H<sub>p</sub>), 7.31 (d, 2H, <sup>3</sup>J=7.6Hz, 2xH<sub>m</sub>), 7.40-7.55 (m, 1H, H-6), 7.65-7.76 (m, 2H, H-7 and H-8), 7.80-7.90 (m, 2H, H-6' and H-5'), 8.49 (d, 1H, <sup>3</sup>J=8.6Hz, H-3'), 8.56 (d, 1H, <sup>3</sup>J=7.8Hz, H-5), 8.70 (d, 1H, <sup>3</sup>J=8.6Hz, H-4'), 9.10 (s, 1H, H-4). <sup>13</sup>C n.m.r. (50 MHz, DMSO-d<sub>6</sub>) δ 34.69 (CH<sub>3</sub>N), 75.90 (PhCH<sub>2</sub>O), 111.11 (C-8), 117.03 (C-7'), 117.43 (C-4), 120.83 (C-4a), 121.02 (C-6), 122.23 (C-5), 123.49 (C-3'), 125.10 (C-5'), 128.06 (C<sub>p</sub> and C<sub>o</sub>), 128.42 (C-4'a), 128.62 (C<sub>m</sub>), 129.39 (C-7), 131.05 (C-6 and C<sub>o</sub>), 136.57 (C-9a), 136.92 (C-8a), 137.05 (C-8'a), 137.57 (C-4'), 141.43 (C-1), 143.44 (C-3), 151.88 (C-8'), 156.72 (C-2') 166.60 (CO); m/z (%) 538 (M<sup>+</sup>, 5).
14. Satisfactory <sup>1</sup>H, <sup>13</sup>C n.m.r. (values assigned by decoupling methods and 2D <sup>1</sup>H-<sup>13</sup>C correlation techniques), mass spectra and elemental analyses were obtained for all new compounds.